News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Egetis presents significant progress towards market at Capital Markets Day today

October 13, 2022

Stockholm, Sweden, October 13, 2022. Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX) is today hosting a Capital Markets Day from 1:00pm-4:00pm CEST at Erik Penser Bank, Apelbergsgatan 27, Stockholm, Sweden, for investors, analysts and media. The event is now fully subscribed for in-person attendance, but it can be followed via a live Webcast from this LINK.

Egetis’ Capital Markets Day will feature a presentation by Dr Edward Visser, Erasmus Medical Center, Rotterdam, The Netherlands, on the unmet medical need and the clinical manifestations of the debilitating disease MCT8 deficiency as well as the positive clinical experience with Egetis’ lead drug candidate Emcitate (tiratricol) treating this condition. Furthermore, a presentation by Professor James Dear, Edinburgh University, Scotland, on the significant burden of paracetamol overdosing and the clinical experience with Egetis’ drug candidate Aladote (calmangafodipir). In addition, members of Egetis’ leadership team and Board will highlight the significant progress made by Egetis towards marketing approvals of Emcitate and Aladote, and the ongoing commercial build out and launch activities. Nicklas Westerholm, CEO at Egetis, will also present Egetis near term strategic objectives and long-term ambitions.
Nicklas Westerholm, CEO at Egetis, said: “I’m delighted to welcome Egetis’ world-leading academic collaborators in their respective field, Dr Edward Visser and Professor James Dear, to present at our Capital Markets Day today. It’s also a pleasure to reflect on how far Egetis has progressed since its formation two years ago. We are well on track to submit a marketing authorisation application in EU in the first half of next year and a new drug application in the US mid-2023 for our lead drug candidate Emcitate paving the way for a launch in 2024.”
Live webcast: Please follow this link
A recording of the event will also be made available on



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10